The influence of Platelet-rich fibrin on the inflammatory response, bone metabolism and cell differentiation ability of Temporomandibular joint osteoarthritis
Sažetak
Objective: This study aims to explore the regulatory effects of platelet-rich fibrin (PRF) on serum inflammatory response, bone metabolic balance and cell differentiation ability in patients with temporomandibular joint osteoarthritis (TMJ-OA) at the molecular levels.
Methods: Sixty patients randomly divided into Group A and Group B (30 cases in each group). Group A was treated with meloxicam dispersible combined with hydroxychloroquine sulfate (HCQ); Group B was supplemented with autologous PRF intra-articular injection on the basis of Group A. Fasting venous blood was collected before treatment and 3 months after treatment. Inflammatory and bone metabolism markers such as IL-1β, IL-6, TNF-α, OPN, ALP, and Runx2 were detected by ELISA, and coagulation indicators such as APTT and PT were determined by an automatic coagulation analyzer.
Results: After treatment, the inflammatory factors (IL-1β, IL-6, TNF-α) in both groups decreased significantly, but the decrease in group B was more significant (P<0.001). Bone metabolism indicators showed that the improvement in group B was significantly better than that in group A (P<0.05). Among the cell differentiation-related factors, the expression levels of Runx2, TGF-β1 and Sox9 in group B were significantly increased compared with those before treatment (P<0.05), and were higher than those in group A (P<0.05). In terms of coagulation function, the APTT and PT in group B were prolonged (P<0.001), and the levels of FIB and D-D decreased (P<0.001).
Conclusion: The use of PRF can optimize the therapeutic effect of TMJ-OA, improve inflammatory responses, promote cell differentiation and reverse the hypercoagulable state of the blood.
Sva prava zadržana (c) 2025 Yuhan Zhao, Hongwei Dai
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.